An antibody derived from a SARS survivor in 2003 appears to effectively neutralize the coronavirus that causes COVID-19, opening the door for speedy development of a targeted treatment.
Technology may lead to rapid diagnosis based on CT scans and patient data.
Global carbon dioxide emissions are down dramatically in the wake of COVID-19. A new study pinpoints where energy demand has dropped the most, estimates the impact on annual emissions and points the way to a less polluted future.
Airborne transmission of viruses, like the virus causing COVID-19, is not well understood, but a good baseline for study is a deeper understanding of how particles travel through the air when people cough. In Physics of Fluids, researchers discuss a simulation they created that examines saliva droplets moving through the air in front of a coughing person. The work shows that with a slight breeze of 4 kph, saliva travels 18 feet in 5 seconds.
As the virus causing COVID-19 began its devastating spread, an international team of scientists was alarmed by the lack of uniform approaches by various countries' epidemiologists. Data modeling to predict the numbers of likely infections varied widely. In the journal Chaos, the group describes why modeling and extrapolating the evolution of COVID-19 outbreaks in near real time is an enormous scientific challenge that requires a deep understanding of the nonlinearities underlying the dynamics of epidemics.
People taken ill by coronavirus infections may experience psychiatric problems while hospitalized and potentially after they recover, suggests an analysis of past research led by the UCL Institute of Mental Health with King's College London collaborators, published in The Lancet Psychiatry.
Scientists from the University of Geneva (UNIGE) and the Geneva University Hospitals (HUG) have studied the most serious consequence of chronic hepatitis: hepatocellular carcinoma. They demonstrated that people infected with Hepatitis D have up to three times the risk of developing that particularly aggressive and often fatal liver cancer compared to those infected only with Hepatitis B. These results, to be read in the Journal of Hepatology, plead for systematic screening of Hepatitis D in patients with Hepatitis B.
An antibody first identified in a blood sample from a patient who recovered from Severe Acute Respiratory Syndrome in 2003 inhibits related coronaviruses, including the one that causes COVID-19. The antibody, called S309, is now on a fast-track development and testing path at Vir Biotechnology in the next step toward possible clinical trials.
Increasing reports of severe COVID-19 illness in children -- coupled with the fact that little is known about how and why the disease may behave differently in this younger population -- demand that a set of critical steps be taken now to ensure children get the attention they need, according to an article just published in Pediatric Research.
A new study led by Marc Veldhoen, group leader at Instituto de Medicina Molecular and published this week in the prestigious Nature Immunology, shows that the local availability of specific molecules is crucial to generate these tissue resident surveillance cells. The impact of these results extends beyond protective immunity in tissues, as these cells are also efficient when elicited after vaccination and yield more effective anti-tumor immunity.